Rutherford, NJ, June 10, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the Sidoti Small Cap Investor Conference. Paul V. Goode, CEO of Glucotrack, will present on Wednesday, June 12, 2024 at 3:15 PM ET and will hold one-on-one meetings. Interested parties may register using the following w ...

Rutherford, NJ, June 10, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the Sidoti Small Cap Investor Conference. Paul V. Goode, CEO of Glucotrack, will present on Wednesday, June 12, 2024 at 3:15 PM ET and will hold one-on-one meetings. Interested parties may register using the following ...

Highly accurate continuous blood glucose monitor demonstrates Mean Absolute Relative Difference (MARD) of 4.7% at Day 90 Continuous blood glucose monitor offers the potential for simplified, discreet and less intrusive glucose monitoring for people with diabetes Rutherford, NJ, June 05, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, ...

Promising results support the potential of epidural glucose monitoring for simplified disease management for patients with painful diabetic neuropathy Rutherford, NJ, May 16, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that its implantable continuous glucose monitor has successfully completed 30 days of a 60-day long-t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-41141 GLUCOTRACK, INC. (Exact name of registrant as specified in its charter) Delaware 98-066 ...

Continuous blood glucose monitor's preclinical data and sensor longevity modeling to be presented at major diabetes conference Rutherford, NJ, May 02, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced two abstracts have been accepted for poster presentation at the American Diabetes Association (ADA) 84th Scientific Sessions ...

Rutherford, NJ, April 22, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that the Company has closed a private placement of securities. The Offering included participation by CEO Paul V. Goode, PhD, as well as other members of the Company's executive management, Board of Directors, and existing shareholders. In a transact ...

Expansion offers the potential for continuous, discreet and simplified epidural glucose monitoring solutions for patients with Painful Diabetic Neuropathy Rutherford, NJ, April 16, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it is expanding its glucose monitoring technology to include measuring glucose in the epidural s ...

Computational modeling with The Technology Partnership shows sensor longevity beyond 3 years; 1 year longer than previously announced Implantable Continuous Blood Glucose Monitor technology could transform lives of patients with diabetes Rutherford, NJ & Cambridge, UK, April 02, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, and The Tec ...

市场销售和医疗保险 - 公司计划利用FDA批准在瑞士市场销售产品[30] - 美国医疗保险覆盖和报销对医疗器械公司的成功至关重要[31] - 预计植入式连续血糖监测产品的销售量和价格将在很大程度上取决于来自医疗保险和第三方支付者的充足报销[32] - 公司正在制定早期的报销计划，以应对CGM技术的当前情况[33] - 公司的报销策略包括产品、植入手术和移除再植入手术的覆盖范围[33] - 美国和欧盟成员国的医疗保健报销、覆盖规定和系统存在显著差异[33] 知识产权和竞争 - 公司正在积极推进知识产权战略，包括在多个司法管辖区进行专利申请[37] - CGM设备市场竞争激烈，主要由Abbott、DexCom和Medtronic主导[39] 财务和风险 - 公司历史上存在运营亏损，未来盈利前景不确定[45] - 公司可能会遇到扩张和运营成功的困难，需要与第三方签订合同来扩展制造、营销和销售能力[46] - 筹集额外资本可能会导致现有股东和投资者的稀释，限制公司运营，或要求公司以不利于公司的条款放弃产品或产品候选人的权利[47] - 公司的独立注册会计师事务所的报告表示对公司作为“持续经营实体”的能力存在重大疑虑[48] - 公司从未在普通股上宣布或支付任何现金股利，未来也不预计在可预见的未来支付任何股利[49] - 如果公司未能符合纳斯达克的继续上市标准，公司的普通股可能会被纳斯达克摘牌[50] - 公司发现了内部财务报告控制方面的重大弱点，可能无法成功实施纠正措施[51] - 经济危机和市场不稳定可能会对公司产品的需求以及通过股票销售融资的能力产生重大不利影响[53] 产品开发和监管 - 公司高度依赖于产品候选人Glucotrack CBGM的成功，无法保证其将获得监管批准或清关或成功商业化[55] - FDA对医疗设备的批准过程昂贵、耗时且不确定，可能阻止公司获得 Glucotrack CBGM 或未来产品候选者的批准[61] - FDA在医疗设备清关或批准过程中拥有相当大的自由裁量权[62] - FDA可能因多种原因推迟、限制或拒绝医疗设备候选者的批准，包括安全性或有效性问题、数据不足等[63] - 获得批准后，产品的清关或批准条款和持续监管可能限制公司的生产和市场营销能力[65] - FDA等监管机构可能改变政策，制定新法规，可能阻止或延迟产品候选者的批准[66]